Company / Return on Equity (ROE)
CUMBERLAND PHARMACEUTICALS INC Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
5.1%
FY2025
5-year range
-27.5% / 5.1%
FY2021-FY2025
Trend
+118.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Equity (ROE) returned to growth in FY2025 after 8 years of decline, reaching 5.1%.
Based on SEC 10-K filings.
5.1% in FY2025 with a 5-year CAGR of +12.2%.
Improved from -18.8% to 5.1% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +14.7pp
- 5-Year Change
- +12.2pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 118.4% year-over-year.
- Lowest return on equity (roe) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 5.1% | +118.4% |
| FY2024 | -27.5% | -46.0% |
| FY2023 | -18.8% | -94.6% |
| FY2022 | -9.7% | -17.1% |
| FY2021 | -8.3% | -16.2% |
| FY2020 | -7.1% | -2.7% |
| FY2019 | -6.9% | -309.5% |
| FY2018 | -1.7% | -248.2% |
| FY2017 | 1.1% | -65.6% |
| FY2016 | 3.3% | +220.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026